UNITED STATES ANTIMONY CORP
UAMYDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
How UAMY's past catalysts played out
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
UB-421 | Phase 2 | HIV-1 Infection | - | - |
Frequently asked questions
What is in UNITED STATES ANTIMONY CORP's drug pipeline?→
CatalystAlert tracks 1 drug candidate in UNITED STATES ANTIMONY CORP's (UAMY) pipeline across Phase 2. Its lead program is UB-421 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is UNITED STATES ANTIMONY CORP's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for UNITED STATES ANTIMONY CORP (UAMY) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track UAMY biotech catalysts?→
Add UAMY to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow UNITED STATES ANTIMONY CORP's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.